[Treatment of essential hypertension with the alpha-1 antagonist bunazosin retard. A multicenter, double-blind, placebo-controlled study].
In a randomised, placebo-controlled design 40 patients with moderately severe essential hypertension were treated with bunazosin (CAS 52712-76-2) retard in increasing doses ranging between 6 and 18 mg/day. In intervals of 14 days titration steps were made, the minimal period of treatment was 4 weeks. In 34 patients (80.6%) a blood pressure response could be achieved with Bunazosin retard alone, the rest of the patients needed the additional administration of 25 mg hydrochlorothiazide daily. In all actively treated patients diastolic blood pressure could be normalised (DBP < or = 90 mmHg). After 4 weeks the mean blood pressure was lowered in the Bunazosin group by 16.2 mmHg (diastolic) and 25 mmHg (systolic). The mean heart rate at rest remained almost constant. Bunazosin was generally well tolerated; only very few adverse events occurred, and no patient collapsed. Compared to placebo the orthostatic tolerance was not influenced by bunazosin retard. Only when changing from resting to standing position the rise in heart rate was slightly more pronounced under bunazosin. Also the physiological blood pressure profile under bunazosin remained unchanged during the orthostatic tests.
Kirsten
R
R
Klinikum der Universität Frankfurt, Abteilung Klinische Pharmakologie, Frankfurt/Main.
Weidinger
G
G
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011187:Posture / Q000502:physiology; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D003692:Delayed-Action Preparations; D011799:Quinazolines; C018176:bunazosin
Behandlung der essentiellen Hypertonie mit dem alpha 1-Antagonisten Bunazosin retard. Eine multizentrisch-doppelblinde, Plazebo-kontrollierte Studie.